Professional Documents
Culture Documents
PHYSIOLOGY
Presented by:
Agus Alim Abdullah
Department of Clinical Pathology
Faculty of Medicine
University of Hasanuddin Makassar
Regulation of hemostatic
mechanism involves complex
interaction between vessels walls,
blood cell elements and a variety of
plasma proteins.
PLATELET STRUCTURE
Major Structure features:
- A typical cell membrane.
- Circumferential microtubular system
- Dense tubular system
- Various granules
- Externally communicating open
canalicular system.
Platelet Membrane
Bilipid membrane and membrane protein.
Bilipid membrane around the platelet
contains several important glycoproteins
that function as surface receptors.
Bilipid membrane is also the site of
complex coagulation activities of the
platelet.
Granules
1. Dense granules contain high concentrations
of ADP and Ca as well as serotonin. These
substances are released upon PLT stimulation,
enhance PLT aggregation.
2. Granules store a variety of proteins that
are secreted by stimulated PLT.
These
includes PF4, -tromboglobulin, PDGF,
Fibrinogen, F V, vWf and various
glycoproteins
important
to
adhesion
(thrombospondin & fibronectin)
Canaliculi
Open canalicular system is a complex
network
of
surface
membrane
invaginations that look like vacuoles.
Increase the PLT surface area.
The contents of PLT granules are
released through this system
Platelet Physiology
Platelet Physiology
AA is converted to cyclic endoperoxides
and TxA2.
Stimulate granules and dense bodies.
High concentration locally thrombin, TxA2
and ADP will change GP IIb-IIIa becomes
receptor for fibrinogen to forms a bond
between adjacent PLT creating a hemostatic
plug.
Phospholipid
Phospholipase
Arachidonic acid
Cyclo-oxygenase
(aspirin inhibits)
PGG2
Peroxidase
PGH2
Thromboxane synthetase
Prostacyclin synthetase
(platelets)
(endothelium)
TxA2
PGI2
H2O
TxB2
6-keto PGIa
Endothelium Contribution
Metabolize AA to Prostacyclin (PGI2).
PGI2 has major contribution as
antithrombotic in intact endothelium.
Low dose aspirin completely block TxA2
production.
Coagulation phase :
1. Conversion of fibrinogen (soluble plasma
protein) into insoluble fibrin affected
by highly specific enzymatic action of
thrombin.
Thrombin must be generated from
zymogen, prothrombin, by a series of
reactions between serine proteases, co
factors & lipid moieties.
Alternative name
Pathway
Half-life
(hours)
I
II
III
V
VII
VIII
IX
X
XI
XII
XIII
HMW kininogen
Prekallikrein
Fibrinogen
Prothrombin
Tissue factor
Proaccelerin
Proconvertin
Antihemophilic factor
Christmas factor
Stuart - Prower factor
Plasma thromboplastin antecedent
Hageman factor
Fibrin - stabilizing factor
Fitzgerald factor
Fletcher factor
C
C
I
C
E
I
I
I,E,C
I
I
I
I
I
90-120
48-120
Not available
12-24
2-6
10-12
18-30
24-60
45-80
40-70
72-200
150
48-52
Coagulation systems :
1. The extrinsic systems : triggered by TF/
tissue factor (complete thromboplastin).
- TF + VIIa + Ca activates F X (F Xa)
- F Xa + V + Lipid (TF) extrinsic prothrombinase (converts prothrombin
thrombin). (Fig 1).
Prothrombin
TF
VIIa
Xa
V
Lipid (TF)
(Ca 2+)
(Ca 2+)
X
Test : PT
(Quick)
Thrombin
Fig.1. Generation of thrombin via the extrinsic system. (TF = tissue fct ;
PT = prothrombin ; = prothrombin complex ; = F X activating
complex).
Contact factors
XII
PK
HMWK
Prothrombin
XIIa
XI
IX
XIa
IXa
VIII
PF3
(Ca 2+)
X
Test : aPTT
Xa
V
Lipid (PF3)
(Ca 2+)
Thrombin
Fig.2.
Prothrombin
Intrinsic system
Extrinsic system
IXa
VIII
VIIIa
PF3
Xa
V
Xa
Va
PF3
Va
V
TF
Thrombin
Fig.3. Autocatalytic action of thrombin. (TF= tissue fct ; PF3 = platelet fct 3)
Prothrombin
Intrinsic system
Extrinsic system
TF
VIIa
XIa
(Ca2+)
IX
IXa
VIII
PF3
(Ca2+)
X
Xa
Thrombin
Fig. 4. Linkage between extrinsic and intrinsic systems. Several interaction
occur at various levels of the two systems. Primary among these is the
ability of TF and F VIIa and F IX.
3. Fibrin generation
When thrombin acts on the fibrinogen
molecu-le, two pairs of tiny fibrinopeptides (A
& B) are cleaved off, yielding activated fibrin
mono-mer units. The monomers polymerize
to form a loose, unstable fibrin clot, which
can be converted to a stable fibrin clot. (Fig.5)
Thrombin
Fibrinogen
Fibrin
Fibrin Polymer
monomer (hydrogen bonded)
Fig. 5. Fibrin generation
a.
b. Additional test
In the reptile time test, the snake venom
employed selectively cleaves fibrinopeptide A
from the fibrinogen molecule. Clotting will
proceed even though fibrinopeptide B
remains intact.
This test can be valuable because it is prolonged in the same circumstances as the TT
except that is not prolonged by the presence
of heparin.
Fibrin stabilization
Final stage of coagulation
F XIII, a transaminase, is activated by thrombin and converts the hydrogen-bonded fibrin
strands into more stable, covalent peptide
bonds. (Fig.6)
Screening test :
Deficiency of F XIIIa results in clots that
dissolve in 5M urea or 1% monochloroacetic acid.
XIII
Thrombin
XIIIa
Fibrin polymer
(hydrogen bonded)
Fibrin polymer
(peptide bonded)
Fibrinolysis
Deposition of fibrin is associated with activation of fibinolysis
Fibrin is a substrate for the proteolytic action
of plasmin.
Plasmin is normally present in its inactive,
zymogen form (plasminogen) in blood, urine
and other body fluids.
Plasminogen may be activated intrinsically
by the contact system of coagulation or extrinsically by TPA/tissue plasminogen activator.
Physiologic inhibitors
Procoagulant & fibrinolytic activities are
homeostatically regulated by counterbalancing natural inhibitors
In the coagulation system, antithrombin III inhibits not only thrombin but
other serine protease as well (F IXa,
Xa, XIa, XIIa).
Plasminogen
Intrinsic system
Extrinsic system
Contact
XII
XIIa
HMWK
Exogenous
Prekallikrein
Kallikrein
TPA
Urokinase
Streptokinase
Plasmin
Fig.7.
INTRINSIC SYSTEM
HMWK
XII
XII a
Kallikrein
XI
XIa
EXTRINSIC SYSTEM
VII
IX
IXa + VIII
Ca 2+
PL
Ca 2+
TF
Ca 2+
Xa + V
Ca 2+
PL
Prothrombin
Thrombin
Fibrinogen
XIII
XIIIa
Fibrin
c. Treatment options :
1. Fresh frozen plasma (FFP)
2. Cryoprecipitate
3. Factor concentrates
5. Complication : Arthropathy, Inhibitors,
Liver disease, HIV infection.
6. Interdisciplinary care hemophilia center
medical care, psychosocial care and
genetic counseling
Finding
Hemophilia A
vWF disease
Normal
Prolonged
Decreased
Decreased
Normal
Decreased
Normal
Decreased
4. Therapy
a. dDVAP
b. Cryoprecipitate
c. F VIII concentrates
3. Diagnosis
- severe : prolonged PT and PTT
- early or milder def. : prolonged PT
4. Therapy
- Parenteral vit. K
- FFP
B. Liver disease
1. Etiology
a. decreased synthesis of coag. factors
b. Vit. K def
4. Therapy
- trial of parenteral vit K therapy
- Replacement therapy FFP
C. Clotting factor inhibitors autoantibodies
1. Inhibitors in hemophilia
2. Inhibitors in patients without preexisting
bleeding disorders
a. Etiology : drugs, autoimmune or
lymphoproliferative disorders,
spontaneous a.coagulants
COAGULATION REGULATION
AND
HYPERCOAGULABLE STATES
Site of action
AT III can inhibit many serine protease
enzymes (Thrombin and factors Xa, IXa
and XIa.
Thrombins central role in coagulation
the most critical site of inactivation.
Protein C
(inactive form of Protein Ca)
Serine protease that acts on specific clotting
factors in the presence of cofactor protein S.
Protein C with the presence of thrombin and
thrombomodulin inhibits on fibrinogen and
platelets.
Sites of action
Coagulation. In the presence of phospholipid and
with protein S as cofactor will inactivates factors
Va and VIIIa.
Fibrinolisis. With protein S as cofactor, protein Ca
enhances fibrinolisis by preventing degradation of
plasminogen avtivator by its inhibitor.
Protein Ca activity is limited by protein C
inhibitor.
B. Fibrinolitic system
1. Activation :
a. Intrinsic activation : a poorly understood
mechanism of activation
b. Extrinsic Activation : Tissue plasminogen
activator (t-PA), urokinase
c. Exogeneous (therapeutic) activation :
streptokinase, urokinase and t-PA
2. Sites of action
a. Fibrinogen
b. Fibrin
II. THROMBOTIC DISORDER
A. Congenital thrombotic disorder
1. AT III deficiency
2. Protein C deficiency
3. Protein S deficiency
b. Pulmonary embolism
c. Arterial thrombosis
d. Other
4. Therapy
a. Agents treatment and prevention
1. Anticoagulants :
- Heparin
- Warfarin
2. Thrombolytic agents :
- Streptokinase
- Urokinase
- t-PA
b. Treatment approaches
1. Deep vein thrombosis : >> heparin,
thrombolytic agent
2. Pulmonary embolus : heparin, thrombolytic
agent
3. Myocardial infarction : thrombolytic agent
4. Peripheral artery and catheter thrombosis :
thrombolytic agent.
4. Therapy :
a. Low grade DIC treatment may not
be necessary
b. Clinically significant bleeding
replacement of depleted coagulation
factors and cells
c. Thrombosis : heparin
THANK YOU